Global Chemotherapy Treatment Market

Chemotherapy (sometimes just called “chemo”) is the use of drugs to kill or slow the growth of cancer cells. The drugs are also called
cytotoxics, which means toxic to cells (cyto).
Chemotherapy Market Size was valued at USD 9.5 billion in 2022. It is projected to reach USD 17.61 billion by 2031, growing at a CAGR of 7.1% during the forecast period (2023–2031). One or more chemotherapeutic agents, such as anti-cancer medications, are used in chemotherapy, a cancer treatment.

Type of Chemotherapy Drug
Alkylating agents
Nitrosoureas
Antimetabolites
Anti-tumor antibiotics
Topoisomerase inhibitors
Mitotic inhibitors
Corticosteroids
Other chemotherapy drugs
All-trans-retinoic acid
Arsenic trioxide
Asparaginase
Eribulin
Hydroxyurea
Ixabepilone
Mitotane
Omacetaxine
Pegaspargase
Procarbazine
Romidepsin
Vorinostat

Chemotherapy Treatment Market Side Effects
Fatigue
Hair loss
Easy bruising and bleeding
Infection
Anemia (low red blood cell counts)
Nausea and vomiting
Appetite changes
Constipation
Diarrhea
Mouth, tongue, and throat problems such as sores and pain with swallowing
Peripheral neuropathy or other nerve problems, such as numbness, tingling, and pain
Skin and nail changes such as dry skin and color change
Urine and bladder changes and kidney problems
Weight changes
Chemo brain, which can affect concentration and focus
Mood changes
Changes in libido and sexual function
Fertility problems

Chemotherapy Market Dynamics
Drivers
Increasing Incidence of Cancer: The global rise in cancer cases is a primary driver of the chemotherapy market. As cancer remains a leading cause of death worldwide, the demand for effective treatment options, including chemotherapy, continues to grow.
Advancements in Chemotherapy Drugs: Innovations in drug formulations and delivery methods have improved the efficacy and reduced the side effects of chemotherapy, driving market growth.
Aging Population: An aging global population is more susceptible to cancer, increasing the need for chemotherapy treatments.
Increased Healthcare Spending: Rising healthcare expenditure, particularly in emerging economies, is facilitating better access to cancer treatments, including chemotherapy.

Restraints
High Treatment Costs: The cost of chemotherapy can be prohibitively expensive, limiting access for many patients, particularly in low-income regions.
Side Effects and Toxicity: Chemotherapy is associated with significant side effects, including nausea, fatigue, and immunosuppression, which can deter its use and affect patient compliance.

Challenges
Drug Resistance: Cancer cells can develop resistance to chemotherapy drugs over time, reducing treatment efficacy and necessitating the development of new drugs.
Stringent Regulatory Requirements: The stringent regulatory environment for the approval and commercialization of chemotherapy drugs can delay market entry and increase costs.
Access to Treatment: In many parts of the world, particularly in developing countries, access to chemotherapy remains limited due to inadequate healthcare infrastructure and economic constraints.

Opportunities
Emerging Markets: Expanding healthcare infrastructure and increasing awareness of cancer treatments in emerging economies present significant growth opportunities for the chemotherapy market.
Personalized Medicine: Advances in personalized medicine, which tailor chemotherapy treatments based on individual genetic profiles, can improve treatment outcomes and reduce side effects.
Combination Therapies: The development of combination therapies that use chemotherapy alongside other treatments, such as immunotherapy or targeted therapy, can enhance efficacy and patient outcomes.
Research and Development: Continued investment in R&D to develop novel chemotherapy agents and improve existing drugs offers substantial growth potential.

Market Segmentation
By Drug Class 
Mitotic Inhibitors
Alkylating Agents 
Antimetabolites 
Topoisomerase Inhibitors 
Antitumor Antibiotic 
By Indication
Breast Cancer
Lung Cancer 
Colorectal Cancer 
Prostate Cancer 
Stomach Cancer 
Lymphoma 
Leukemia 
Ovarian Cancer 
By Route of Drug Administration 
Intravenous 
Oral 
Subcutaneous
Intra-Muscular 
Intravesicular 
Topical 
Intraperitoneal and 
Intraventricular/Intrathecal 
By End-User 
Specialty Centers 
Hospitals 
Clinics 
By Region
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America

Key Companies in the chemotherapy market include

Johnson & Johnson Services Inc (US)
GlaxoSmithKline PLC (UK)
Eli Lilly and Company (US)
F. Hoffmann-La Roche Ltd (Switzerland)
Novartis AG (Switzerland)
Pfizer Inc. (US)

Merck & Co. Inc. (US)
Sanofi S.A. (France)
Celgene Corporation (US)
Bristol-Myers Squibb 

Chemotherapy Industry Developments 
August 2022:Ipsen announced the completion of the definitive merger agreement that would see Ipsen acquire Epizyme, Inc. (Epizyme). Tazverik (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor awarded Accelerated Approval by US Food and Drug Administration in 2020, is acquired by Ipsen as part of the agreement. 
September 2020:Gilead Sciences Inc announced a $21 billion acquisition of Immunomedics Inc, boosting its cancer portfolio by obtaining access to a promising medicine. The agreement grants Gilead access to Immunomedics' breast cancer treatment medicine Trodelvy, which received fast FDA approval in April for an aggressive and difficult-to-treat kind of breast cancer.